The mortality of COVID-19 in CML patients from 2020 until 2022: results from the EPICOVIDEHA survey

• Authors: EL-ASHWAH Shaimaa; SALMANTON-GARCIA Jon; BILGIN Yavuz M; ITRI Federico; ZAK Pavel; WEINBERGEROVÁ Barbora; VERGA Luisa; OMRANI Ali S; SILVA Maria Gomes da; SZOTKOWSKI Tomas; MARCHETTI Monia; BUQUICCHIO Caterina; NUCCI Marcio; SCHOENLEIN Martin; FARINA Francesca; BESSON Caroline; PREZIOSO Lucia; NIZAMUDDIN Summiya; DAVILA-VALLS Julio; MARTIN-PEREZ Sonia; BONUOMO Valentina; JAAP Van Doesum; TISI Maria Chiara; PASSAMONTI Francesco; MENDEZ Gustavo-Adolfo; MEERS Stef; MAERTENS Johan; LOPEZ-GARCIA Alberto; GLENTHOJ Andreas; BONNANI Matteo; RINALDI Ikhwan; ORMAZABAL-VELEZ Irati; LABRADOR Jorge; KULASEKARARAJ Austin; ESPIGADO Ildefonso; DEMIRKAN Fatih; NICK De Jonge; COLLINS Graham P; CALBACHO Maria; BLENNOW Ola; AL-KHABORI Murtadha; ADZIC-VUKICEVIC Tatjana; ARELLANO Elena; MISKOVIC Bojana; MLADENOVIC Milos; NORDLANDER Anna; RACIL Zdenek; AMMATUNA Emanuele; CORDOBA Raul; HERSBY Ditte Stampe; GRAEFE Stefanie; EMARAH Ziad; HANAKOVA Michaela; SACCHI Maria Vittoria; IJAZ Marriyam; RAHIMLI Laman; RAQUEL Nunes Rodrigues; ZAMBROTTA Giovanni Paolo Maria; MARCHESI Francesco; CORNELY Oliver A; PAGANO Livio
• Year of publication: 2024
• Type: Article in Periodical
• Magazine / Source: LEUKEMIA & LYMPHOMA
• MU Faculty or unit: Faculty of Medicine
• Web: https://www.tandfonline.com/doi/full/10.1080/10428194.2023.2280886
• Doi: http://dx.doi.org/10.1080/10428194.2023.2280886
• Keywords: Chronic myeloid leukemia; tirosine kinase inhibitor; COVID-19; SARS-CoV-2; neoplasia; vaccines
• Description: Since the beginning of the COVID-19 pandemic, there has been an overall improvement in patient mortality. However, haematological malignancy patients continue to experience significant impacts from COVID-19, including high rates of hospitalization, intensive care unit (ICU) admissions, and mortality. In comparison to other haematological malignancy patients, individuals with chronic myeloid leukemia (CML) generally have better prognosis. This study, conducted using a large haematological malignancy patient database (EPICOVIDEHA), demonstrated that the majority of CML patients experienced mild infections. The decline in severe and critical infections over the years can largely be attributed to the widespread administration of vaccinations and the positive response they elicited. Notably, the mortality rate among CML patients was low and exhibited a downward trend in subsequent years. Importantly, our analysis provided confirmation of the effectiveness of vaccinations in CML patients.